Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received European Commission, or EC, approval of a new Opdivo – nivolumab – subcutaneous formulation developed with Enhanze, Halozyme’s proprietary recombinant human hyaluronidase enzyme, for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib. The positive EC decision is supported by positive results from the Phase 3 CheckMate -67T trial. The approval by the EC is valid in all 27 member states of the European Union, as well as Iceland, Liechtenstein and Norway.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Optimistic Buy Rating for Halozyme Amid Price Control Concerns
- Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
- Hold Rating Issued Amid Uncertainty in Drug Pricing Regulations Impacting Halozyme
- UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
- Halozyme, J&J slide as analyst cuts rating on CMS draft guidance